Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SolventumFRA:KB7 28 EV-to-EBIT is 10.17 as of Aug. 05, 2026, which is 13% below its 10-year median of 11.71. GuruFocus rates FRA:KB7 with a GF Score™ of 28/100. The stock has 8 warning signs investors should review. Among 470 Medical Devices & Instruments companies, Solventum ranks better than 77.23% on this metric.
The historical rank and industry rank for Solventum's EV-to-EBIT or its related term are showing as below:
FRA:KB7'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.09 Med: 11.71 Max: 28.4
Current: 10.03
During the past 6 years, the highest EV-to-EBIT of Solventum was 28.40. The lowest was 7.09. And the median was 11.71.
FRA:KB7's EV-to-EBIT is ranked better than 77.23% of 470
companies
in the Medical Devices & Instruments industry
Industry Median: 19.07
vs FRA:KB7: 10.03
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Solventum's Enterprise Value for the quarter that ended in Mar. 2026 was €13,667 Mil.
Solventum's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,705 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solventum EV-to-EBIT Related Terms
Solventum EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Solventum's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Solventum's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solventum EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Solventum's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Solventum's EV-to-EBIT falls into.
Solventum's current Enterprise Value is €17,342 Mil.
Solventum's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,705 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solventum (FRA:KB7) has a EV-to-EBIT of 10.17 as of Aug. 05, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solventum and its competitors. This is 13% below median its historical median of 11.71. Over the past decade, Solventum's EV-to-EBIT has ranged from 7.09 to 28.40. According to the industry distribution chart, Solventum ranks #107 out of 470 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is Solventum's EV-to-EBIT too high?
Solventum's current EV-to-EBIT of 10.17 is 13% below median its 10-year median of 11.71. Over the past 10 years, this metric has ranged from a low of 7.09 to a high of 28.40. The Medical Devices & Instruments industry median EV-to-EBIT is 19.07. Solventum's value of 10.17 is 46.7% below this industry median. Based on the distribution chart, Solventum ranks #107 out of 470 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Solventum has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Solventum's EV-to-EBIT compare to COO and ALGN?
According to the Medical Devices & Instruments industry distribution chart, Solventum ranks #107 out of 470 companies for EV-to-EBIT. This places Solventum in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.07. Solventum's value of 10.17 is 46.7% below this benchmark. Historically, Solventum's own EV-to-EBIT has ranged from 7.09 to 28.40 over the past decade. While the company's 10-year median is 11.71 vs. the industry median of 19.07, Solventum has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.07, based on 470 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solventum's current EV-to-EBIT of 10.17 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Solventum and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solventum's current EV-to-EBIT is 10.17, which is 13% below median its own 10-year median of 11.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solventum stock overvalued right now?
Solventum (FRA:KB7) has a current EV-to-EBIT of 10.17. The current EV-to-EBIT is 10.17, which is 13% below median its 10-year median of 11.71 and 46.7% below the Medical Devices & Instruments industry median of 19.07. Solventum's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Solventum (FRA:KB7), the current EV-to-EBIT is 10.17 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solventum Corp is a healthcare company developing, manufacturing, and commercializing solutions leveraging material science, data science, and digital capabilities to address customer and patient needs. Its segments include MedSurg, which earns maximum revenue and provides wound therapy, I.V. site management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and OEM medical technologies; Dental Solutions, offering dental and orthodontic products such as brackets, restorative cements, and bonding agents; and Health Information Systems, providing software solutions including physician documentation, coding automation, speech recognition, and data visualization platforms. It operates in the United States, which earns the majority of revenue, and internationally.
28GF Score
Get the complete analysis for FRA:KB7
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:KB7 has been successfully added to your 
